SRNE Stock Price: Sorrento Therapeutics Inc. plummets after FDA pivots to plasma to treat COVID-19
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- NASDAQ:SRNE drops nearly 20% as investors continue to lose faith in the biotech firm.
- The U.S. government shifts its focus to convalescent plasma treatments, amongst others.
It has been a steady decline for NASDAQ:SRNE since shares briefly neared the 52-week highs just two weeks ago. Sorrento’s stock is now down nearly 60% since the August 10th peak of $18.82 per share – bringing the price down below its 50-day moving average. While shares of Sorrento are still up over 350% over the past year, these high levels of volatility have come with the territory of being one of the players involved in the great race known as Operation Warp Speed.
On Sunday, the U.S. FDA announced that it would be granting Emergency Use Authorization (EUA) for convalescent plasma to treat coronavirus patients in America. While this should not be looked at as a defeat for Sorrento, it does show the first signs of the FDA shifting its focus away from traditional pharmaceutical vaccines. The Financial Times also reported that the Trump Administration is leaning towards choosing U.K. biotech firm AstraZeneca (NYSE:AZN) to supply its COVID-19 vaccine to American citizens this fall. Neither of these news pieces are good news for Sorrento or any other biotech company involved in the race for the coronavirus vaccine. Industry rivals Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), and Inovio (NASDAQ:INO) were all down as well to start the week.
SRNE Stock Forecast
Recent Wall Street analyst reports are favorable for Sorrento despite its current downward trajectory. H.C. Wainwright has issued a buy rating and a target price of $30 while Dawson James also rated the firm a buy with a target price of $24. Either outlook provides plenty of growth for SRNE although both reports came before the FDA’s announcement over the weekend.
- NASDAQ:SRNE drops nearly 20% as investors continue to lose faith in the biotech firm.
- The U.S. government shifts its focus to convalescent plasma treatments, amongst others.
It has been a steady decline for NASDAQ:SRNE since shares briefly neared the 52-week highs just two weeks ago. Sorrento’s stock is now down nearly 60% since the August 10th peak of $18.82 per share – bringing the price down below its 50-day moving average. While shares of Sorrento are still up over 350% over the past year, these high levels of volatility have come with the territory of being one of the players involved in the great race known as Operation Warp Speed.
On Sunday, the U.S. FDA announced that it would be granting Emergency Use Authorization (EUA) for convalescent plasma to treat coronavirus patients in America. While this should not be looked at as a defeat for Sorrento, it does show the first signs of the FDA shifting its focus away from traditional pharmaceutical vaccines. The Financial Times also reported that the Trump Administration is leaning towards choosing U.K. biotech firm AstraZeneca (NYSE:AZN) to supply its COVID-19 vaccine to American citizens this fall. Neither of these news pieces are good news for Sorrento or any other biotech company involved in the race for the coronavirus vaccine. Industry rivals Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), and Inovio (NASDAQ:INO) were all down as well to start the week.
SRNE Stock Forecast
Recent Wall Street analyst reports are favorable for Sorrento despite its current downward trajectory. H.C. Wainwright has issued a buy rating and a target price of $30 while Dawson James also rated the firm a buy with a target price of $24. Either outlook provides plenty of growth for SRNE although both reports came before the FDA’s announcement over the weekend.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.